Drug Development
Codagenix pursues RSV vaccine development amid unexpected challenges
Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.
ImmPACT Bio begins dosing in Phase I/II lymphoma therapy trial
Precision and personalised medicine is rapidly expanding beyond oncology
Ionis concludes enrolment in Phase III amyloid cardiomyopathy trial
Merck’s Phase III breast cancer therapy trial meets primary endpoint
Chinook begins subject enrolment in Phase III IgA nephropathy trial
